Brief Report: Association of Rheumatoid Factor and Anti–Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan‐European Registry Analysis
Open Access
- 27 January 2016
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 68 (6) , 1346-1352
Abstract
Objective: To investigate the role of rheumatoid factor (RF) status and anti–citrullinated peptide antibody (ACPA) status as predictors of abatacept (ABA) effectiveness in patients with rheumatoid arthritis (RA).Methods: We conducted a pooled analysis of data from 9 observational RA registries in Europe (ARTIS [Sweden], ATTRA [Czech Republic], BIOBADASER [Spain], DANBIO [Denmark], GISEA [Italy], NOR‐DMARD [Norway], ORA [France], Reuma.pt [Portugal], and SCQM‐RA [Switzerland]). Inclusion criteria were a diagnosis of RA, initiation of ABA treatment, and available information on RF and/or ACPA status. The primary end point was continuation of ABA treatment. Secondary end points were ABA discontinuation for ineffectiveness or adverse events and response rates at 1 year (good or moderate response according to the European League Against Rheumatism criteria with LUNDEX adjustment for treatment continuation). Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for the study end points in relation to RF and ACPA status were calculated.Results: We identified 2,942 patients with available data on RA‐associated autoantibodies; data on RF status were available for 2,787 patients (77.0% of whom were RF positive), and data on ACPA status were available for 1,903 patients (71.3% of whom were ACPA positive). Even after adjustment for sociodemographic and disease‐ and treatment‐related confounders, RF and ACPA positivity were each associated with a lower risk of ABA discontinuation for any reason (HR 0.79 [95% CI 0.69–0.90], P < 0.001 and HR 0.78 [95% CI 0.68–0.90], P < 0.001, respectively), compared to RF‐negative and ACPA‐negative patients. Similar associations with RF and ACPA were observed for discontinuation of ABA treatment due to ineffectiveness, with HRs of 0.72 (95% CI 0.61–0.84) and 0.74 (95% CI 0.62–0.88), respectively (both P < 0.001).Conclusion: Our results strongly suggest that positivity for RF or ACPA is associated with better effectiveness of ABA therapy.Keywords
Funding Information
- Bristol Myers-Squibb
This publication has 20 references indexed in Scilit:
- Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION studyBMC Musculoskeletal Disorders, 2015
- Non-HLA genes PTPN22, CDK6 and PADI4 are associated with specific autoantibodies in HLA-defined subgroups of rheumatoid arthritisArthritis Research & Therapy, 2014
- Longterm Followup of Rituximab Therapy in Patients with Rheumatoid Arthritis: Results from the Belgian MabThera in Rheumatoid Arthritis RegistryThe Journal of Rheumatology, 2014
- Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registryAnnals of the Rheumatic Diseases, 2012
- Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registriesAnnals of the Rheumatic Diseases, 2011
- Anti-CCP antibodies: the past, the present and the futureNature Reviews Rheumatology, 2011
- B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: A six‐month, national, multicenter, open‐label studyArthritis & Rheumatism, 2011
- A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis RegistriesSeminars in Arthritis and Rheumatism, 2010
- Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritisArthritis Research & Therapy, 2005
- Redefining the HLA and RA association: To be or not to be anti-CCP positiveJournal of Autoimmunity, 2005